
Soleno Therapeutics (SLNO) Stock Forecast & Price Target
Soleno Therapeutics (SLNO) Analyst Ratings
Bulls say
Soleno Therapeutics Inc. has demonstrated a positive financial trajectory with preliminary unaudited net revenues for full-year 2025 estimated at $190 million, including a robust $92 million generated in the fourth quarter alone. The company's strong product adoption and market access are reflected in the receipt of 1,250 total new patient start forms, indicating approximately 12.5% penetration into the addressable U.S. market for VYKAT XR. Additionally, Soleno maintains a solid cash position projected at around $500 million by the end of 2025, which supports its strategic initiatives for mergers and acquisitions or licensing opportunities.
Bears say
Soleno Therapeutics Inc faces a negative outlook primarily due to challenges related to market access and reimbursement issues impacting the uptake of its DCCR product. Furthermore, there are concerns regarding the potential for earlier-than-expected generic competition that could erode the DCCR franchise, coupled with the company’s difficulties in optimizing the value of DCCR in international markets. Additionally, risks surrounding slower-than-anticipated U.S. market performance further exacerbate the company's financial position, leading to a reconsideration of its stock valuation.
This aggregate rating is based on analysts' research of Soleno Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Soleno Therapeutics (SLNO) Analyst Forecast & Price Prediction
Start investing in Soleno Therapeutics (SLNO)
Order type
Buy in
Order amount
Est. shares
0 shares